Hs-CRP in cardiovascular prevention

1. In primary prevention (those who have NOT had a heart attack) , persistently elevated hsCRP should prompt consideration of statin initiation or intensification, irrespective of LDL-C 2. In secondary prevention (those known to have heart disease) , hsCRP is at least as powerful a predictor of recurrent events as LDL-C 3. Low-dose colchicine should be considered for patients with chronic stable ischemic heart disease, particularly those with hsCRP >2 mg/L despite aggressive lipid-lowering therapy IMPORTANT CAVEAT No direct anti-inflammatory trial has yet been completed in a purely primary prevention heart disease-free population, though trials of IL-6 inhibitors (ziltivekimab) are anticipated to report in late 2026–